27F with androgenic alopecia since 17 seeks treatment. Tried spironolactone, caused low blood pressure; believes finasteride is safer and wants to try it.
RU58841 and pyrilutamide are being discussed as potential hair loss treatments, with some users reporting side effects. There is interest in these treatments as alternatives to 5ar inhibitors and oral minoxidil due to concerns about safety and side effects.
PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.
Higher doses of Dutasteride, like 2.5 mg daily, may offer slightly more hair growth but come with increased risk of side effects, such as sexual dysfunction and sleep disturbances. Many users suggest starting with a lower dose, like 1 mg, to minimize side effects while still achieving effective results.
Bicalutamide blocks androgen receptors, preventing testosterone and DHT from binding, which can help with hair loss but may cause feminization. It is not recommended for those who do not want feminization effects.
A satirical take on the effects of using Verteporfin as a treatment for hair loss, with people pointing out that it is not accurate and has exaggerated outcomes. It was suggested that instead Minoxidil, Finasteride, or RU58841 should be used to treat hair loss.
Breezula's potential as a hair loss treatment is debated, with some seeing promise despite delays, while others suggest alternatives like Pyrilutamide. Breezula is compared to topical finasteride, with hopes for a better side effect profile.
The conversation is about finding a legitimate and affordable Chinese source for RU58841 powder for hair loss treatment. It suggests choosing a vendor with good reviews and testing the product for authenticity.
A user struggled with hair loss and ineffective vitamin treatments from their doctor. They eventually obtained a finasteride prescription through a telemedicine service and felt relieved.
Hair loss treatments Fin and Minoxidil failed for user. Suggested alternatives are 75mg oral spiro and RU58841, but concerns about low testosterone and self-esteem were raised.
The user is experiencing a lack of morning erections after using 0.5mg of finasteride every other day for two weeks and is considering whether to reduce the dose, continue, or stop. The discussion focuses on adjusting finasteride dosage due to side effects.
RU58841 is considered effective by some users, but finasteride and minoxidil are commonly used with varying dosages to manage side effects. Users report different experiences with treatments like pyrilutamide, fluridil, and RU58841, with some seeing results and others not.
Crushing finasteride pills into stemoxydine may not be effective without removing the coating first. It's unclear if the pills dissolve completely or settle as sediment.
A user is considering dutasteride mesotherapy versus oral finasteride for hair loss, with concerns about side effects. Other users share experiences with both treatments, suggesting oral finasteride as more effective and cost-efficient, while also discussing the use of minoxidil, alfatradiol, and potential side effects like gynecomastia.
The conversation discusses using higher doses of minoxidil and finasteride, considering dutasteride, and exploring other treatments like RU58841 for hair preservation. The user reports no side effects after six months and is interested in advanced treatment combinations.
The user is considering adding an anti-androgen, RU58841, to their current hair loss treatment routine due to receding hair. They are also contemplating waiting for Breezula or Pyrilutamide to become more affordable.
Genetic variations influence how people respond to dutasteride for hair loss, with some benefiting more from finasteride. Dutasteride is effective for most, but genetic differences may cause it to be less effective for some.
Creating a topical solution combining finasteride and stemoxydine to treat hair loss, and the discussion of whether 15mg of finasteride would be sufficient for 60ml solvent.
A user with diffuse thinning, currently using finasteride, biotin, minoxidil, and nizoral shampoo, is considering a topical solution called "82M" but is skeptical due to its high cost and lack of supporting research. They seek others' experiences with "82M."
PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.
The conversation is about someone planning to start finasteride for hair loss and wanting to interpret pre-treatment blood panels to assess the risk of side effects like gynecomastia. They list various tests to measure hormone levels and other health indicators.
A person transitioning is using 2mg sublingual estradiol and 2.5mg oral minoxidil daily for hair regrowth, noting significant progress in three months. They plan to increase estrogen dosage and consider adding dutasteride, discussing the effects and challenges of transitioning.
Adding exosomes to a treatment of dutasteride and minoxidil for hair loss increased hair count by 55% at 6 months and 46% at 1 year compared to the control group. The control group did not receive exosomes or PRP.
A user started taking 0.5 mg of finasteride daily and noticed watery semen, questioning if it's normal or if they should adjust the dosage. Another user suggested it might indicate reduced fertility and may not improve.
A user shared their success in getting a prescription for 0.1% Alfatradiol, a topical treatment for hair loss similar to finasteride but with fewer side effects. They found a pharmacy to compound it and will update on the results.
A user is deciding between oral and topical finasteride for hair loss, noting oral finasteride's ease of use but broader effects. Another user simply recommends oral finasteride.
The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.
A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.
The conversation discusses a new product from Actifolic, which combines RU58841 and GHK-CU for hair loss treatment. The participants are considering whether it's worth trying.